உயிரியல் நிறுவனம் வரையறுக்கப்பட்டவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from உயிரியல் நிறுவனம் வரையறுக்கப்பட்டவை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In உயிரியல் நிறுவனம் வரையறுக்கப்பட்டவை Today - Breaking & Trending Today

Bibcol to produce 1 crore doses of Covaxin per month at Bulandshahr plant in UP


Bibcol to produce 1 crore doses of Covaxin per month at Bulandshahr plant in UP
Bibcol to produce 1 crore doses of Covaxin per month at Bulandshahr plant in UP
Bibcol will produce 1 crore Covaxin doses every month, starting September, at its plant in Bulandshahr. The production capacity will be increased to 2 crore doses per month in the future. The Union Health Ministry has said it will provide Rs 30 crore to Bibcol for the production of Covaxin.
advertisement
UPDATED: May 21, 2021 09:57 IST
A man receives Bharat Biotech s Covid-19 vaccine Covaxin, at a vaccination centre, in New Delhi. (Photo:Reuters)
Amid a shortage of anti-coronavirus vaccines in India, the Centre has given its nod for manufacturing of Covaxin by Bibcol at its plant in Uttar Pradesh’s Bulandshahr. Covaxin is an indigenous vaccine developed by Bharat Biotech. ....

Andhra Pradesh , Uttar Pradesh Bulandshahr , Narendra Modi , Bharat Immunologicals , Rajiv Kumar Shukla , Arvind Kejriwal , Union Health Ministry , Indian Immunologicals Limited , Haffkine Biopharmaceutical Corporation Ltd , Biologicals Corporation Limited Bibcol , Health Ministry , Uttar Pradesh , Biologicals Corporation Limited , Vice Chairman Rajiv Kumar Shukla , Bibcolv C , Bharat Biotech , Supports Augmentation , Manufacturing Capacity , Delhi Chief Minister Arvind Kejriwal , Prime Minister Narendra Modi , Covishield Rut , Niti Aayog , Bibcol To Produce Covaxin , Covaxin Bharat Biotech , Harat Biotech Ropes In Bibcol , ஆந்திரா பிரதேஷ் ,

Waiving patents on Covid-19 vaccines won't be enough to ramp up supplies


consensus among member states. The European Commission
said it would begin discussions on waivers but Germany, home to BioNTech, the firm that created the vaccine being marketed by Pfizer, said it
opposed a waiver because “the protection of the intellectual property is a source of innovation and must remain so”.
However, the Indian government has taken a different line domestically: At a hearing in India’s Supreme Court this month, the court asked the government whether it intended to issue any compulsory licenses to companies to manufacture drugs like remdesivir that are being used for Covid-19 treatment.
The government reportedly ....

South Africa , Ad Daw Ah , United States , United Kingdom , South African , Bharat Immunologicals , Bill Gates , Shivangi Mittal , Gopakumar Nair , Tedros Adhanom Ghebreyesus , Leena Menghaney , Davinder Gill , Sudarshan Jain , Murali Neelakantan , Sanford Bernstein , Astrazeneca Covishield , Indian Immunologicals Ltd , World Trade Organization On , Melinda Gates Foundation , International Federation Of Pharmaceutical Manufacturers , Biologicals Corporation , India Supreme Court , Serum Institute , Serum Institute Of India , Indian Pharmaceutical Alliance , World Health Organization ,